Form 4: Tarsus Pharmaceuticals Executive Sells Shares
Insider Transaction (Form 4)
Elizabeth Yeu Lin, Chief Medical Officer of Tarsus Pharmaceuticals, Inc., sold 11,578 shares of common stock on September 1, 2026.
Summary
- Open-market sale: disposed of 4,601 Common Stock at $73.86 ($339,830) on September 1, 2026; holds 18,707 after (Direct).
- Open-market sale: disposed of 5,387 Common Stock at $80.00 ($430,960) on September 2, 2026; holds 13,320 after (Direct).
- Open-market sale: disposed of 1,590 Common Stock at $80.00 ($127,200) on September 2, 2026; holds 4,770 after (Indirect).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $897,990 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Elizabeth Yeu Lin — Officer (Chief Medical Officer)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-01 | Open-market sale | Common Stock | 4,601 | $74 | $339.8K | 18,707 |
| 2026-09-02 | Open-market sale | Common Stock | 5,387 | $80 | $431.0K | 13,320 |
| 2026-09-02 | Open-market sale | Common Stock | 1,590 | $80 | $127.2K | 4,770 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-01 | Open-market sale (4,601 shares) |
| 2026-09-02 | Open-market sale (5,387 shares) |
| 2026-09-02 | Open-market sale (1,590 shares) |
Keywords
insider transaction, Form 4, TARS, Tarsus Pharmaceuticals, Inc., bearish, Elizabeth Yeu Lin
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.